by Matthew LePoire | Uncategorized in , , ,

051 – Amarin Receives UNANIMOUS Recommendation from Advisory Committee

I’m back! Here are the companies I touch on in this video:

Sarepta: 2:30
Trevena: 4:08
Viking: 5:40
Regenxbio: 7:47
Biogen: 12:35
Amarin: 17:38

all of this is only opinion and nothing I have said should be taken as investment advice

http://www.breakingbiotech.com

 

One thought on “051 – Amarin Receives UNANIMOUS Recommendation from Advisory Committee”

  1. Looking forward to reading your comments on the FDA approval on Vascepa/Amarin from Friday 🙂

    Reply

Leave a Reply

%d bloggers like this: